AGTC

Agtc

Biotechnology, Alachua, Florida, United States, 51-200 Employees

agtc.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 16*********

Who is AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with a...

Read More

map
  • Alachua, Florida, United States Headquarters: Alachua, Florida, United States
  • 1999 Date Founded: 1999
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $50 Million to $100 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541715 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from AGTC

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding AGTC

Answer: AGTC's headquarters are located at Alachua, Florida, United States

Answer: AGTC's phone number is 16*********

Answer: AGTC's official website is https://agtc.com

Answer: AGTC's revenue is $50 Million to $100 Million

Answer: AGTC's SIC: 2836

Answer: AGTC's NAICS: 541715

Answer: AGTC has 51-200 employees

Answer: AGTC is in Biotechnology

Answer: AGTC contact info: Phone number: 16********* Website: https://agtc.com

Answer: AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products Find AGTC on YouTube at goo.gl/sMdJqX.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access